Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
Other Sizes |
|
References |
|
---|
Molecular Formula |
C20H20O5
|
---|---|
Molecular Weight |
340.38
|
Exact Mass |
340.131
|
CAS # |
53846-50-7
|
Appearance |
Solid powder
|
Density |
1.3±0.1 g/cm3
|
Boiling Point |
597.6±50.0 °C at 760 mmHg
|
Flash Point |
216.4±23.6 °C
|
Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
Index of Refraction |
1.642
|
LogP |
5.28
|
SMILES |
CC(=CCC1=C2C(=C(C=C1O)O)C(=O)C[C@H](O2)C3=CC=C(C=C3)O)C
|
InChi Key |
LPEPZZAVFJPLNZ-SFHVURJKSA-N
|
InChi Code |
InChI=1S/C20H20O5/c1-11(2)3-8-14-15(22)9-16(23)19-17(24)10-18(25-20(14)19)12-4-6-13(21)7-5-12/h3-7,9,18,21-23H,8,10H2,1-2H3/t18-/m0/s1
|
Chemical Name |
(2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-8-(3-methylbut-2-enyl)-2,3-dihydrochromen-4-one
|
Synonyms |
Sophoraflavanone B YS04 Flavaprenin 8-Prenylnaringenin 8 Prenylnaringenin 8Prenylnaringenin
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~250 mg/mL (~734.49 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.11 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.11 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.11 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.9379 mL | 14.6895 mL | 29.3789 mL | |
5 mM | 0.5876 mL | 2.9379 mL | 5.8758 mL | |
10 mM | 0.2938 mL | 1.4689 mL | 2.9379 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT03140397 | COMPLETED | Dietary Supplement: Placebo Dietary Supplement: 6-prenylnaringenin Dietary Supplement: 8-prenylnaringenin |
Immune Cells Activity Pharmacokinetics After Oral Intake Safety After Oral Intake |
University of Hohenheim | 2016-01 | Early Phase 1 |
NCT05524714 | COMPLETED | Dietary Supplement: solubilized Xanthohumol low dose Dietary Supplement: solubilized Xanthohumol high dose Dietary Supplement: native Xanthohumol low dose Dietary Supplement: native Xanthohumol high dose |
Plasmakinetics of Xanthohumol | University of Bonn | 2022-08-01 | Not Applicable |
NCT02848430 | COMPLETED | Dietary Supplement: Humulus lupulus | Food-Drug Interactions | University of Illinois at Chicago | 2016-08-15 | Not Applicable |
NCT03735420 | ACTIVE, NOT RECRUITINGWITH RESULTS | Drug: Xanthohumol Drug: Placebo oral capsule |
Healthy | National University of Natural Medicine | 2019-08-12 | Phase 1 |
Accumulation and distribution of 10 µm naringenin and 8-prenylnaringenin in BJ and U-118 MG cells after 24 h incubation. Green signal was derived from flavonoid autofluorescence and blue signal from DAPI-stained nuclei. Scale bar 30 µm.[3].In Vitro Effect of 8-Prenylnaringenin and Naringenin on Fibroblasts and Glioblastoma Cells-Cellular Accumulation and Cytotoxicity. Molecules. 2017 Jun 30;22(7). td> |
Accumulation of 10 µM naringenin or 8-prenylnaringenin in normal fibroblasts (BJ) and glioblastoma cells (U-118 MG) after 24 h treatment. Data presented as the mean of Corrected Total Cell Fluorescence. Error bars represent mean ± 1.96 * SE. Statistically significant differences are marked as arrows for p < 0.05 (Student’s t-test).[3].In Vitro Effect of 8-Prenylnaringenin and Naringenin on Fibroblasts and Glioblastoma Cells-Cellular Accumulation and Cytotoxicity. Molecules. 2017 Jun 30;22(7).. td> |